Euvichol Or Euvichol-Plus Market Report 2026

Euvichol Or Euvichol-Plus Market Overview

• The Euvichol Or Euvichol-Plus market growth in the historic period has been driven by limited treatment options for cholestasis, increasing prevalence of gallstone disease • Market expansion is supported by rising incidence of nafld, expanding liver disease screening programs • Growth Driver: Rising Liver Diseases Prevalence To Drive Growth Of The Market • Market Trend: Innovative Oral Cholera Vaccine To Enhance Usability And Safety • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Euvichol Or Euvichol-Plus Market?

Euvichol and euvichol-plus are pharmaceutical products used primarily in the treatment of liver diseases, especially those associated with cholestasis, gallstones, and primary biliary cirrhosis (PBC). These medications are both ursodeoxycholic acid (UDCA)-based treatments, with Euvichol-Plus being a combination therapy. The main types of products in euvichol or euvichol-plus are euvichol and euvichol-plus. Euvichol is an oral cholera vaccine primarily used for preventing cholera in regions where the disease is endemic or during outbreaks. It includes various clinical indications, such as non-alcoholic fatty liver disease (NAFLD), liver dysfunction, and detoxification and liver protection, and is distributed through hospitals and clinics, pharmacies, and public health campaigns.

What Is The Euvichol Or Euvichol-Plus Market Growth Forecast?

The growth in the forecast period can be attributed to rising incidence of nafld, expanding liver disease screening programs, growing demand for combination liver therapies, improved access to hepatology care, increasing healthcare spending on chronic diseases. Major trends in the forecast period include growing adoption of udca-based liver therapies, rising use in cholestatic liver disorders, combination therapies for enhanced liver protection, increasing diagnosis of chronic liver diseases, expansion of preventive liver care programs.

Global Euvichol Or Euvichol-Plus Market Segmentation

1) By Product Type: Euvichol, Euvichol-Plus 2) By Clinical Indication: Non-Alcoholic Fatty Liver Disease (NAFLD), Liver Dysfunction, Detoxification And Liver Protection 3) By Distribution Channel: Hospitals And Clinics, Pharmacies, Public Health Campaigns

What Are The Drivers Of The Euvichol Or Euvichol-Plus Market?

The growing prevalence of liver diseases is anticipated to drive the future growth of the euvichol or euvichol-plus market in the coming years. Liver diseases refer to a range of medical conditions that affect the liver, impairing its ability to function properly. The increasing prevalence of liver diseases is largely due to rising obesity rates, which contribute to non-alcoholic fatty liver disease, and excessive alcohol consumption, a major cause of alcoholic liver disease. Euvichol and Euvichol Plus are used to manage liver diseases, particularly chronic hepatitis B, by improving liver cell membrane integrity, reducing inflammation, and supporting liver function. For instance, in April 2024, according to the GOV.UK, a UK-based government agency, hospital admission rates for liver disease increased to 155.2 per 100,000 population in the financial year ending 2023, up from 150.6 per 100,000 in 2022. Therefore, the increasing prevalence of liver diseases is driving the growth of the euvichol or euvichol-plus industry. The rise in healthcare expenditure is expected to propel the growth of the euvichol or euvichol-plus market going forward. Healthcare expenditure refers to the total spending on healthcare services, including hospital care, medical research, pharmaceuticals, public health programs, and other related services. The rise in healthcare expenditure is driven by several factors, including an aging population, increased prevalence of chronic diseases, advancements in medical technology, and rising treatment costs. Healthcare expenditure supports broader distribution and accessibility of euvichol and euvichol-plus, enhancing cholera prevention efforts in vulnerable populations. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government agency, total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, compared to a growth rate of 0.9% in 2022. Therefore, the rise in healthcare expenditure drives the growth of the euvichol or euvichol-plus industry.

Key Players In The Global Euvichol Or Euvichol-Plus Market

Major companies operating in the euvichol or euvichol-plus market are Eubiologics Co. Ltd., Techinvention Lifecare Pvt. Ltd.

Global Euvichol Or Euvichol-Plus Market Trends and Insights

A key trend in the euvichol or euvichol-plus market is the development of technologically advanced solutions, such as the oral cholera vaccine, to meet various critical industry needs. Oral cholera vaccines are vaccines taken by mouth to protect against cholera, a bacterial infection that causes severe diarrhea and dehydration. For instance, in May 2023, Techinvention Lifecare Pvt. Ltd., an India-based biotechnology company, introduced Euvichol-Plus, the first oral cholera vaccine packaged in a low-density polyethylene (LDPE) unidose pack. This innovative packaging enhances usability and safety by minimizing the risks of breakage and waste typically associated with traditional glass vials. Approved by the Central Drugs Standard Control Organization (CDSCO) following a successful phase III clinical trial, Euvichol-Plus addresses a significant public health need in India, where approximately 400 million people are at risk of cholera. The vaccine is expected to improve distribution during emergencies and humanitarian crises, supporting global efforts to eradicate cholera by 2030.

Regional Insights

North America was the largest region in the euvichol or euvichol-plus market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Euvichol Or Euvichol-Plus Market?

The euvichol or euvichol-plus market consists of sales of products including ursofalk, actigall, and generic ursodeoxycholic acid (UDCA) formulations. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Euvichol Or Euvichol-Plus Market Report 2026?

The euvichol or euvichol-plus market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the euvichol or euvichol-plus industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.